Meningococcal Vaccines Market (By Type: Combination Vaccines [MenHibrix, Menitorix], Conjugate Vaccines [Menactra, MenAfriVac, Meningitec, Menjugate, Menveo, NeisVac-C, Nimenrix, NmVac4-DT], Polysaccharide [Mencevax, Menomune, NmVac4, Others], Men B Vaccines [Bexsero, Trumenba], Others; By End User: Retail Pharmacies, Hospital Pharmacies, Others) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026

Category : Healthcare and Pharmaceuticals | Delivery Format: PDF | Status: Published | Pages : 190

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Meningococcal Vaccines
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Meningococcal Vaccines Market By Type
1.2.2.1. Global Meningococcal Vaccines Market Revenue and Growth Rate Comparison By Type (2015-2026)
1.2.2.2. Global Meningococcal Vaccines Market Revenue Share By Type in 2017
1.2.2.3. Combination Vaccines
1.2.2.3.1. MenHibrix
1.2.2.3.2. Menitorix
1.2.2.4. Conjugate Vaccines
1.2.2.4.1. Menactra
1.2.2.4.2. MenAfriVac
1.2.2.4.3. Meningitec
1.2.2.4.4. Menjugate
1.2.2.4.5. Menveo
1.2.2.4.6. NeisVac-C
1.2.2.4.7. Nimenrix
1.2.2.4.8. NmVac4-DT
1.2.2.5. Polysaccharide
1.2.2.5.1. Mencevax
1.2.2.5.2. Menomune
1.2.2.5.3. NmVac4
1.2.2.5.4. Others
1.2.2.6. Men B Vaccines
1.2.2.6.1. Bexsero
1.2.2.6.2. Trumenba
1.2.2.6.3. Others
1.2.3. Meningococcal Vaccines Market By End User
1.2.3.1. Global Meningococcal Vaccines Market Revenue and Growth Rate Comparison By End User (2015-2026)
1.2.3.2. Global Meningococcal Vaccines Market Revenue Share By End User in 2017
1.2.3.3. Retail Pharmacies
1.2.3.4. Hospital Pharmacies
1.2.3.5. Others
1.2.4. Meningococcal Vaccines Market by Geography
1.2.4.1. Global Meningococcal Vaccines Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.4.2. North America Meningococcal Vaccines Market Revenue and Growth Rate (2015-2026)
1.2.4.3. Europe Meningococcal Vaccines Market Revenue and Growth Rate (2015-2026)
1.2.4.4. Asia-Pacific Meningococcal Vaccines Market Revenue and Growth Rate (2015-2026)
1.2.4.5. Latin America Meningococcal Vaccines Market Revenue and Growth Rate (2015-2026)
1.2.4.6. Middle East and Africa (MEA) Meningococcal Vaccines Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Meningococcal Vaccines Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Meningococcal Vaccines Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Meningococcal Vaccines Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Meningococcal Vaccines Major Manufacturers in 2017

CHAPTER 4. MENINGOCOCCAL VACCINES MARKET BY FORM

4.1. Global Meningococcal Vaccines Revenue By Type
4.2. Combination Vaccines
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Conjugate Vaccines
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Polysaccharide
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Men B Vaccines
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. MENINGOCOCCAL VACCINES MARKET BY END USER

5.1. Global Meningococcal Vaccines Revenue By End User
5.2. Retail Pharmacies
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Hospital Pharmacies
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Others
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET BY COUNTRY

6.1. North America Meningococcal Vaccines Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2. North America Meningococcal Vaccines Market Revenue Share Comparison, 2015 & 2026 (%)
6.3. U.S.
6.3.1. U.S. Meningococcal Vaccines Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
6.4. Canada
6.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
6.5. Mexico
6.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
6.5.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)

CHAPTER 7. EUROPE MENINGOCOCCAL VACCINES MARKET BY COUNTRY

7.1. Europe Meningococcal Vaccines Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. Europe Meningococcal Vaccines Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. UK
7.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
7.4. Germany
7.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
7.5. France
7.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
7.6. Spain
7.6.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.6.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
7.7. Rest of Europe
7.7.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.7.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)

CHAPTER 8. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET BY COUNTRY

8.1. Asia-Pacific Meningococcal Vaccines Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Asia-Pacific Meningococcal Vaccines Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. China
8.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
8.4. Japan
8.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
8.5. India
8.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
8.6. Australia
8.6.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
8.7. South Korea
8.7.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
8.8. Rest of Asia-Pacific
8.8.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.8.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)

CHAPTER 9. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET BY COUNTRY

9.1. Latin America Meningococcal Vaccines Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Latin America Meningococcal Vaccines Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. Brazil
9.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
9.4. Argentina
9.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
9.5. Rest of Latin America
9.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)

CHAPTER 10. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET BY COUNTRY

10.1. Middle East Meningococcal Vaccines Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Middle East Meningococcal Vaccines Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Saudi Arabia
10.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
10.4. UAE
10.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
10.5. Rest of Middle East
10.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)

CHAPTER 11. AFRICA MENINGOCOCCAL VACCINES MARKET BY COUNTRY

11.1. Africa Meningococcal Vaccines Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Africa Meningococcal Vaccines Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. South Africa
11.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
11.4. Egypt
11.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
11.5. Rest of Africa
11.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)

CHAPTER 12. COMPANY PROFILE

12.1. Baxter International
12.1.1. Company Snapshot
12.1.2. Overview
12.1.3. Financial Overview
12.1.4. Product Portfolio
12.1.5. Key Developments
12.1.6. Strategies
12.2. Biomed Pvt. Ltd.
12.2.1. Company Snapshot
12.2.2. Overview
12.2.3. Financial Overview
12.2.4. Product Portfolio
12.2.5. Key Developments
12.2.6. Strategies
12.3. GlaxoSmithKline plc
12.3.1. Company Snapshot
12.3.2. Overview
12.3.3. Financial Overview
12.3.4. Product Portfolio
12.3.5. Key Developments
12.3.6. Strategies
12.4. JN-International Medical Corporation
12.4.1. Company Snapshot
12.4.2. Overview
12.4.3. Financial Overview
12.4.4. Product Portfolio
12.4.5. Key Developments
12.4.6. Strategies
12.5. Novartis International
12.5.1. Company Snapshot
12.5.2. Overview
12.5.3. Financial Overview
12.5.4. Product Portfolio
12.5.5. Key Developments
12.5.6. Strategies
12.6. Nuron Biotech
12.6.1. Company Snapshot
12.6.2. Overview
12.6.3. Financial Overview
12.6.4. Product Portfolio
12.6.5. Key Developments
12.6.6. Strategies
12.7. Pfizer Inc.
12.7.1. Company Snapshot
12.7.2. Overview
12.7.3. Financial Overview
12.7.4. Product Portfolio
12.7.5. Key Developments
12.7.6. Strategies
12.8. Sanofi SA
12.8.1. Company Snapshot
12.8.2. Overview
12.8.3. Financial Overview
12.8.4. Product Portfolio
12.8.5. Key Developments
12.8.6. Strategies
12.9. Serum Institute of India Ltd
12.9.1. Company Snapshot
12.9.2. Overview
12.9.3. Financial Overview
12.9.4. Product Portfolio
12.9.5. Key Developments
12.9.6. Strategies
12.10. Others
12.10.1. Company Snapshot
12.10.2. Overview
12.10.3. Financial Overview
12.10.4. Product Portfolio
12.10.5. Key Developments
12.10.6. Strategies

CHAPTER 13. RESEARCH APPROACH

13.1. Research Methodology
13.1.1. Initial Data Search
13.1.2. Secondary Research
13.1.3. Primary Research
13.2. Assumptions and Scope


Cart Summary